Immunotherapy with Allergen Peptides

Allergy, Asthma & Clinical Immunology

Mark Larché¹ 

[1] Department of Allergy and Clinical Immunology, Faculty of Medicine, Imperial College, South Kensington, London

关键词: T cell;    regulatory T cell;    peptide;    immunotherapy;    immunological tolerance;    IL-10;    epitope;    allergy;   

Others  :  1083823
DOI  :  10.1186/1710-1492-3-2-53

【 授权许可】

   
2007 Canadian Society of Allergy and Clinical Immunology

【 参考文献 】

• [1]Akdis M, Verhagen J, Taylor A, et al.: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004, 199:1567-75.
• [2]Cookson W: Genetics and genomics of asthma and allergic diseases. Immunol Rev 2002, 190:195-206.
• [3]Gale EA: A missing link in the hygiene hypothesis? Diabetologia 2002, 45:588-94.
• [4]Wraith DC, Nicolson KS, Whitley NT: Regulatory CD4(+) T cells and the control of autoimmune disease. Curr Opin Immunol 2004, 16:695-701.
• [5]Ling EM, Smith T, Nguyen XD, et al.: Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004, 363:608-15.
• [6]Verhagen J, Akdis M, Traidl-Hoffmann C, et al.: Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006, 117:176-83.
• [7]Karlsson MR, Rugtveit J, Brandtzaeg P: Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004, 199:1679-88.
• [8]Ou LS, Goleva E, Hall C, Leung DY: T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004, 113:756-63.
• [9]de Kleer IM, Wedderburn LR, Taams LS, et al.: CD4+CD25 bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004, 172:6435-43.
• [10]Arif S, Tree TI, Astill TP, et al.: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-63.
• [11]Balandina A, Lecart S, Dartevelle P, et al.: Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-41.
• [12]Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102(4 Pt 1):558-62.
• [13]Abramson M, Puy R, Weiner J: Immunotherapy in asthma: an updated systematic review. Allergy 1999, 54:1022-41.
• [14]Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-75.
• [15]Pajno GB, Barberio G, De Luca F, et al.: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001, 31:1392-7.
• [16]Moller C, Dreborg S, Ferdousi HA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-6.
• [17]Polosa R, Al Delaimy WK, Russo C, et al.: Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005, 6:153. BioMed Central Full Text
• [18]Secrist H, Chelen CJ, Wen Y, et al.: Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993, 178:2123-30.
• [19]Varney VA, Hamid QA, Gaga M, et al.: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993, 92:644-51.
• [20]Ebner C, Siemann U, Bohle B, et al.: Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997, 27:1007-15.
• [21]Wachholz PA, Nouri-Aria KT, Wilson DR, et al.: Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002, 105:56-62.
• [22]Aalberse RC, van der GR, van Leeuwen J: Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4- restricted response. J Immunol 1983, 130:722-6.
• [23]Jeannin P, Lecoanet S, Delneste Y, et al.: IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998, 160:3555-61.
• [24]Jutel M, Akdis M, Budak F, et al.: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33:1205-14.
• [25]Akdis CA, Akdis M, Blesken T, et al.: Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996, 98:1676-83.
• [26]Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003, 111:1255-61.
• [27]Nouri-Aria KT, Wachholz PA, Francis JN, et al.: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004, 172:3252-9.
• [28]Nasser S, Ying S, Meng Q, et al.: Interleukin 10 levels increase in cutaneous biopsies of patients undergoing venom immunotherapy. Eur J Immunol 2001, 31:3704-13.
• [29]Critchfield JM, Racke MK, Zuniga-Pflucker JC, et al.: T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994, 263:1139-43.
• [30]Gaur A, Wiers B, Liu A, et al.: Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992, 258:1491-4.
• [31]Burkhart C, Liu GY, Anderton SM, et al.: Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol 1999, 11:1625-34.
• [32]Ku G, Kronenberg M, Peacock DJ, et al.: Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur J Immunol 1993, 23:591-9.
• [33]Staines NA, Harper N, Ward FJ, et al.: Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 1996, 103:368-75.
• [34]Prakken BJ, van Der ZR, Anderton SM, et al.: Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA 1997, 94:3284-9.
• [35]Daniel D, Wegmann DR: Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996, 93:956-60.
• [36]Tian J, Atkinson MA, Clare-Salzler M, et al.: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996, 183:1561-7.
• [37]Bockova J, Elias D, Cohen IR: Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. J Autoimmun 1997, 10:323-9.
• [38]Briner TJ, Kuo MC, Keating KM, et al.: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993, 90:7608-12.
• [39]Hoyne GF, O'Hehir RE, Wraith DC, et al.: Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993, 178:1783-8.
• [40]Bauer L, Bohle B, Jahn-Schmid B, et al.: Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997, 107:536-41.
• [41]King TP, Lu G, Agosto H: Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides. J Allergy Clin Immunol 1998, 101:397-403.
• [42]von Garnier C, Astori M, Kettner A, et al.: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000, 30:1638-45.
• [43]Norman PS, Ohman JL, Long AA, et al.: Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996, 154(6 Pt 1):1623-8.
• [44]Haselden BM, Kay AB, Larche M: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope- induced late asthmatic reactions. J Exp Med 1999, 189:1885-94.
• [45]Marcotte GV, Braun CM, Norman PS, et al.: Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998, 101(4 Pt 1):506-13.
• [46]Pene J, Desroches A, Paradis L, et al.: Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998, 102(4 Pt 1):571-8.
• [47]Simons FE, Imada M, Li Y, et al.: Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996, 8:1937-45.
• [48]Maguire P, Nicodemus C, Robinson D, et al.: The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999, 93:222-31.
• [49]Oldfield WL, Kay AB, Larche M: Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001, 167:1734-9.
• [50]Oldfield WL, Larche M, Kay AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:47-53.
• [51]Alexander C, Ying S, Kay B, Larche M: Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005, 35:52-8.
• [52]Smith TR, Alexander C, Kay AB, et al.: Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. Allergy 2004, 59:1097-101.
• [53]Alexander C, Tarzi M, Larche M, Kay AB: The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005, 60:1269-74.
• [54]Verhoef A, Alexander C, Kay AB, Larche M: T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med 2005, 2:e78.
• [55]Muller U, Akdis CA, Fricker M, et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998, 101(6 Pt 1):747-54.
• [56]Texier C, Pouvelle S, Busson M, et al.: HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000, 164:3177-84.
• [57]Tarzi M, Klunker S, Texier C, et al.: Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006, 36:465-74.
• [58]Fellrath JM, Kettner A, Dufour N, et al.: Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003, 111:854-61.